Notice of Change to Eligibility Information and Key Dates in RFA-HL-20-009 "BLOODSAFE (UG3/UH3 Clinical Trial Optional)" and Announcement of Availability of FAQs

Notice Number: NOT-HL-19-691

Key Dates
Release Date: April 12, 2019

Related Announcements

RFA-HL-20-009

RFA-HL-20-010

NOT-HL-19-694

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

On March 11, 2019, NHLBI issued RFA-HL-20-009, "BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (UG3/UH3 Clinical Trial Optional)". The purpose of this Notice is to change the key dates and to clarify the Eligibility Information.

Key Dates

Application Due Date(s)

Current Language:

May 20, 2019, by 5:00 PM local time of applicant organization.

Revised Language:

June 11, 2019, by 5:00 PM local time of applicant organization.

Scientific Merit Review

Current Language:

November 2019

Revised Language:

December 2019

Expiration Date

Current Language:

May 21, 2019

Revised Language

June 12, 2019

Section III. Eligibility Information

1. Eligible Applicants

Eligible Individuals (Program Director/Principal Investigator)

Current Language:

The primary PD/PI must have a academic appointment at an institution in a low income or lower-middle income country (by the World Bank criteria) in Sub-Saharan Africa. This academic affiliation must constitute at least 50% of the PD/PI full time professional effort in the past 2 years.

Revised Language:

The primary PD/PI should have an appointment at an institution in a low income or lower-middle income country (by the World Bank criteria) in Sub-Saharan Africa. This affiliation should constitute at least 50% of the PD/PI full time professional effort in the past 2 years.

All other aspects of this FOA remain unchanged.

This Notice is also to inform potential applicants that NHLBI has posted a set of responses to Frequently Asked Questions (FAQs) regarding RFA-HL-20-009. The FAQs are available on the NHLBI website at the following link: https://www.nhlbi.nih.gov/node-general/frequently-asked-questions-bloodsafe-research-enhance-availability-safe-blood-patients, which may be updated when additional questions are asked.

Inquiries

Please direct all inquiries to:

Shimian Zou, PhD
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0065
Email: shimian.zou@nih.gov

LeShawndra Price, PhD
Center for Translation Research and Implementation Science
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8166
Email: leshawndra.price@nih.gov